(Q34296771)

1 August 2017

1 reference

title

Paclitaxel: epirubicin in metastatic breast cancer--a review (English)

1 reference

1 August 2017

1 reference

ChEBI release 2020-05-28

1 reference

2

G Fountzilas

1 reference

1 August 2017

E D Razis

1

1 reference

1 August 2017

publication date

1 May 2001

1 reference

1 August 2017

1 reference

1 August 2017

volume

12

1 reference

1 August 2017

issue

5

1 reference

1 August 2017

page(s)

593-598

1 reference

Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011108807105

7 January 2021

Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011108807105

7 January 2021

Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011108807105

7 January 2021

Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011108807105

7 January 2021

Combined doxorubicin and paclitaxel in advanced breast cancer: Effective and cardiotoxic

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011108807105

7 January 2021

Drugs ten years later: epirubicin.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011108807105

7 January 2021

A phase II study of paclitaxel in advanced breast cancer resistant to anthracyclines

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011108807105

7 January 2021

A phase II trial of weekly high-dose folinic acid and 5-fluorouracil in combination with epirubicin as salvage chemotherapy in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011108807105

7 January 2021

Pharmacokinetics of taxol and doxorubicin administered alone and in combination by continuous 72-hour infusion

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011108807105

7 January 2021

Comparative effects of paclitaxel and docetaxel on the metabolism and pharmacokinetics of epirubicin in breast cancer patients

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011108807105

7 January 2021

Sequence effect of epirubicin and paclitaxel treatment on pharmacokinetics and toxicity

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011108807105

7 January 2021

Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: a regimen with high activity and low cardiotoxicity in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011108807105

7 January 2021

Cardiotoxicity of epirubicin/paclitaxel-containing regimens: role of cardiac risk factors

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011108807105

7 January 2021

Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011108807105

7 January 2021

Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. The Piedmont Oncology Association

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011108807105

7 January 2021

Eastern Cooperative Oncology Group randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011108807105

7 January 2021

Paclitaxel by 3-h infusion and carboplatin in anthracycline-resistant advanced breast cancer. A phase II study conducted by the Hellenic Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1011108807105

7 January 2021

Identifiers

DOI

10.1023/A:1011108807105

1 reference

1 August 2017

1 reference